Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
November 28, 2023 17:05 ET
|
Arvinas Inc.
-- Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib (IBRANCE®) -- NEW HAVEN, Conn. and NEW YORK, Nov. 28,...
Arvinas Announces Oversubscribed $350 Million Private Placement
November 27, 2023 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule
November 23, 2023 07:47 ET
|
Curium
Curium, a global leader in nuclear medicine, announced today the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial.
Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 22, 2023 08:05 ET
|
Celcuity Inc.
MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its...
Η CURIUM ΑΝΑΚΟΙΝΏΝΕΙ ΌΤΙ ΟΙ ΠΡΏΤΟΙ ΑΣΘΕΝΕΊΣ ΣΤΗΝ ΕΛΛΆΔΑ ΈΛΑΒΑΝ ΈΝΕΣΗ ΜΕ PYLCLARI® - ΈΝΑΝ ΚΑΙΝΟΤΌΜΟ ΙΧΝΗΘΈΤΗ PET 18F-PSMA ΠΟΥ ΕΝΔΕΊΚΝΥΤΑΙ ΣΕ ΑΣΘΕΝΕΊΣ ΜΕ ΚΑΡΚΊΝΟ ΤΟΥ ΠΡΟΣΤΆΤΗ
November 16, 2023 05:14 ET
|
Curium US LLC
ΠΑΡΙΣΙ, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Η Curium, παγκόσμιος ηγέτης στην πυρηνική ιατρική, ανακοίνωσε σήμερα ότι σε συνεργασία με τον αποκλειστικό διανομέα της SYN Innovation Laboratories στην...
Curium Announces First Patients in Europe Injected With PYLCLARI® – an Innovative 18F-PSMA Pet Tracer Indicated in Patients With Prostate Cancer
November 16, 2023 05:14 ET
|
Curium
PARIS, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that in partnership with its exclusive distributor SYN Innovation Laboratories in Greece, the...
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
November 13, 2023 07:05 ET
|
Celcuity Inc.
Received FDA clearance of IND to evaluate gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer (mCRPC) Entered into a...
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023 07:00 ET
|
Arvinas Inc.
– Enrollment continues in the 2L Phase 3 VERITAC-2 trial and study lead-in for the VERITAC-3 1L Phase 3 trial with vepdegestrant; Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – –...
Arvinas to Participate in Upcoming Investor Conferences
November 02, 2023 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Prostate Cancer Minimally Invasive Surgery Market Size is Envisioned to Grow at a CAGR of 3.6% and reach USD 3.9 billion by 2031|Report by TMR
November 01, 2023 13:00 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. The global prostate cancer minimally invasive surgery market stood at US$ 2.9 billion in 2022...